Search Results

You are looking at 161 - 170 of 521 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

receive perioperative chemotherapy, including both neoadjuvant and adjuvant therapy. 23 Although a certain proportion of patients may be poor candidates for therapy based on comorbidity or impaired renal function (thereby precluding cisplatin

Full access

Photodynamic Therapy and Antitumor Immunity

Sandra O. Gollnick

improved response when we used PDT lysate.” These vaccines seemed to inhibit the growth of both new and established tumors, suggesting their clinical potential as an adjuvant therapy. The generation of effective vaccines depends on active metabolism, at

Full access

Measuring Opportunities to Improve Timeliness of Breast Cancer Care at Dana-Farber/Brigham and Women’s Cancer Center

Craig A. Bunnell, Katya Losk, Sarah Kadish, Nancy Lin, Judith Hirshfield-Bartek, Linda Cutone, Kristen Camuso, Mehra Golshan, and Saul Weingart

. The data included the following milestones: diagnosis by needle biopsy, first definitive surgery, last definitive surgery, and adjuvant therapy timing (chemotherapy, radiation therapy, or endocrine therapy). NCCN also provided benchmarking data for the

Full access

Strategies for the Management of Early-Stage Breast Cancer in Older Women

Lee S. Schwartzberg and Sarah L. Blair

/carboplatin/trastuzumab. 5 years of tamoxifen reduced recurrences in patients aged 65 years and older. 13 “Based on these data, for the ‘younger’ older woman completing 5 years of adjuvant therapy who is at risk for recurrence, an additional 5 years of treatment is

Full access

Update on Immunotherapy for Melanoma

Antoni Ribas

. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma . J Clin Oncol 2006 ; 24 : 1188 – 1194 . 17. Spitler LE Grossbard ML Ernstoff MS . Adjuvant therapy of stage III and IV malignant

Full access

New Agents for Colorectal Cancer

Mary F. Mulcahy and Al B. Benson III

G . Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma: German Cancer Aid 17-1A Study Group . Lancet 1994 ; 343 : 1177 – 1183 . 37 Riethmuller G Holz E Schlimok G . Monoclonal

Full access

Colon Cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

Weeks J . Controversies regarding laparoscopic colectomy for malignant diseases . Curr Opin Gen Surg 1994 : 208 – 213 . 65 Sun W Haller DG . Adjuvant therapy of colon cancer . Semin Oncol 2005 ; 32 : 95 – 102 . 66 Baddi L

Full access

Practice-Changing Interventions in the Systemic Management of Breast Cancer

Presented by: William J. Gradishar

Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from

Full access

Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers

Presented by: Maura L. Gillison

(ClinicalTrials.gov identifier: NCT03952585 ). “Those that exceed the landmark PFS and MDADI scores could move forward in a randomized phase III trial,” she said. Can Adjuvant Therapy Be Altered After Primary Surgical Resection? ECOG 3311 was the first

Full access

Updates to the Management of Endometrial Cancer

Presented by: Nadeem R. Abu-Rustum

tumors tend to fare well, so treatment de-escalation might be appropriate for a patient with surgical stage I disease. “But I am not comfortable saying we can avoid adjuvant therapy in a patient with stage III/IV disease,” he added. “They also do well